Evelo Biosciences, Inc., a biotechnology company based in Delaware, has filed Post-Effective Amendment No. 1 with the U.S. Securities and Exchange Commission (SEC) on January 26, 2024, to deregister unsold securities under two previous registration statements. The affected securities were initially registered for the company's 2021 Employment Inducement Award Plan and its 2015 Stock Incentive Plan, 2018 Incentive Award Plan, and 2018 Employee Stock Purchase Plan. This move follows the company's board of directors' decision on November 21, 2023, to dissolve the company in accordance with the Delaware General Corporation Law, pending stockholder approval. The deregistration effectively terminates the offerings of securities under the specified registration statements, aligning with the company's plan to dissolve.

Evelo Biosciences, Inc., a biotechnology company based in Delaware, has filed Post-Effective Amendment No. 1 with the U.S. Securities and Exchange Commission (SEC) on January 26, 2024, to deregister unsold securities under two previous registration statements. The affected securities were initially registered for the company's 2021 Employment Inducement Award Plan and its 2015 Stock Incentive Plan, 2018 Incentive Award Plan, and 2018 Employee Stock Purchase Plan. This move follows the company's board of directors' decision on November 21, 2023, to dissolve the company in accordance with the Delaware General Corporation Law, pending stockholder approval. The deregistration effectively terminates the offerings of securities under the specified registration statements, aligning with the company's plan to dissolve.